title: Chemotherapy with FUDR in the management of metastatic renal cell carcinoma.
abstract: Metastatic renal cell carcinoma has a poor prognosis, requiring systemic therapy, in addition to radical nephrectomy. Since August 1989, 50 patients were treated with continuous, systemic, chronobiological infusion of FUDR (floxuridine) at our Institution. We reported 11.7% of objective responses, a long period of stable disease and low toxicity. We also compared our actuarial survival with the results obtained with recombinant IL-2 treatment.
authors.affiliation: Clinica Urologica dell'Università di Torino, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Aveta
authors.forename: C
authors.initials: C
authors.lastname: Terrone
authors.forename: D
authors.initials: D
authors.lastname: Neira
authors.forename: C
authors.initials: C
authors.lastname: Cracco
authors.forename: S
authors.initials: S
authors.lastname: Rocca Rossetti
mesh_terms: D000206:Actuarial Analysis; D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary*; D017024:Chemotherapy, Adjuvant; D019454:Chronotherapy; D005260:Female; D005467:Floxuridine / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D015918:Infusion Pumps, Implantable; D007376:Interleukin-2 / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D000964:Antimetabolites, Antineoplastic; D007376:Interleukin-2; D005467:Floxuridine